Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1177-1186

  Corbera Bellalta, Marc ^a   Planas Rigol, Ester ^a   Lozano, Ester ^a   Terrades García, Nekane ^a   Alba, Marco A ^a   Prieto González, Sergio ^a   García Martínez, Ana ^a   Albero, Robert ^a   Enjuanes, Anna ^a   Espígol Frigolé, Georgina ^a   Hernández Rodríguez, José ^a   Roux Lombard, Pascale ^b   Ferlin, Walter G ^c   Dayer, Jean Michel ^d   Kosco Vilbois, Marie H ^b   Cid, Maria C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c NOVIMMUNE SA   (Switzerland)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; MATRIGEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A6; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT GAMMA INTERFERON; STAT1 PROTEIN; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; CXCL10 PROTEIN, HUMAN; CXCL11 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

ARTICLE; BLOOD VESSEL WALL; CELL ADHESION; CELL ADHESION ASSAY; CELL INFILTRATION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; GENE EXPRESSION; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MACROPHAGE; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPORAL ARTERY; TISSUE CULTURE; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CHEMOTAXIS; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; TISSUE CULTURE TECHNIQUE; VASCULAR SMOOTH MUSCLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; CHEMOKINES, CXC; CHEMOTAXIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; GIANT CELL ARTERITIS; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MALE; MUSCLE, SMOOTH, VASCULAR; STAT1 TRANSCRIPTION FACTOR; TEMPORAL ARTERIES; TISSUE CULTURE TECHNIQUES;

EID: 84954271113     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208371     Document Type: Article

References (56)

1. Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012;8:509-21.
2. Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine 2014;93:194-201.
3. Cid MC, Font C, Coll-Vinent B, et al. Large vessel vasculitides. Curr Opin Rheumatol 1998;10:18-28.
4. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
5. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004;43:294-301.
6. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
7. Corbera-Bellalta M, García-Martínez A, Lozano E, et al. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis 2014;73:616-23.
8. Ciccia F, Alessandro R, Rizzo A, et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011;63:2097-104.
9. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-15.
10. Terrier B, Geri G, Chaara W, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012;64:2001-11.
11. Visvanathan S, Rahman MU, Hoffman GS, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology (Oxford) 2011;50:2061-70.
12. Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012;64:3788-98.
13. Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2013;72:1481-7.
14. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
15. Qiao Y, Giannopoulou EG, Chan CH, et al. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. Immunity 2013;39:454-69.
16. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009;31:539-50.
17. Saha B, Jyothi Prasanna S, Chandrasekar B, et al. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010;50:1-14.
18. Hu X, Park-Min KH, Ho HH, et al. IFN-gamma-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-gamma responses mediated by Stat1. J Immunol 2005;175:3637-47.
19. Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004;279:41679-85.
20. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37.
21. Gough DJ, Levy DE, Johnstone RW, et al. IFNγ signalling- does it mean JAK-STAT? Cytokine Growth Factor Rev 2008;19:383-94.
22. Lozano E, Segarra M, García-Martínez A, et al. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 2008;67:1581-8.
23. Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93.
24. Cid MC, Hoffman MP, Hernández-Rodríguez J, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford) 2006;45:1356-63.
25. Cid MC, Cebrián M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000;43:184-94.
26. Weyand CM, Wagner AD, Björnsson J, et al. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;98:1642-9.
27. Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997;99:2842-50.
28. Segarra M, García-Martínez A, Sánchez M, et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007;66:1429-35.
29. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013;9:731-40.
30. Ly KH, Regent A, Tamby MC, et al. Pathogenesis of giant-cell arteritis: more than just an inflammatory condition?. Autoimmunity Rev 2010;9:635-45.
31. Marinescu VD, Kohane IS, Riva A. The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. Nucleic Acids Res 2005;33:D91-7.
32. Braun M, Pietsch P, Felix SB, et al. Modulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on human coronary smooth muscle cells by cytokines. J Mol Cell Cardiol 1995;27:2571-9.
33. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity 2014;41:694-707.
34. Wang M, Jiang L, Monticone RE, et al. Proinflammation: the key to arterial aging. Trends Endocrinol Metab 2014;25:72-9.
35. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002;46:457-66.
36. Shin WS, Hong YH, Peng HB, et al. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity. J Biol Chem 1996;271:11317-24.
37. Kovacic JC, Gupta R, Lee AC, et al. Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 2010;120:303-14.
38. Zhao DX, Hu Y, Miller GG, et al. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002;169:1556-60.
39. Tellides G, Tereb DA, Kirkiles-Smith NC, et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000;403:207-11.
40. Tellides G, Pober JS. Inflammatory and immune responses in the arterial media. Circ Res 2015;116:312-22.
41. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 2015;116:307-11.
42. Ogilvie RL, Sternjohn JR, Rattenbacher B, et al. Tristetraprolin mediates interferon-gamma mRNA decay. J Biol Chem 2009;284:11216-23.
43. Ishmael FT, Fang X, Galdiero MR, et al. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol 2008;180:8342-53.
44. Liberman AC, Refojo D, Druker J, et al. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J 2007;21:1177-88.
45. Wagner AD, Björnsson J, Bartley GB, et al. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996;148:1925-33.
46. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008;29:479-86.
47. Kelchtermans H, Schurgers E, Geboes L, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009;11:R122.
48. Bhatt AS, Manzo VE, Pedamallu CS, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol 2014;66:1939-44.
49. Weck KE, Dal Canto AJ, Gould JD, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 1997;3:1346-53.
50. Shimizu K, Shichiri M, Libby P, et al. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004;114:300-8.
51. King VL, Lin AY, Kristo F, et al. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 2009;119:426-35.
52. Tang PC, Yakimov AO, Teesdale MA, et al. Transmural inflammation by interferon-gamma-producing T cells correlates with outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms. FASEB J 2005;19:1528-30.
53. García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008;59:422-30.
54. Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 2015;74:129-35.
55. Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989-94.
56. García-Martínez A, Arguis P, Prieto-González S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis 2014;73:1826-32.